Abstract
Drugs for several diseases are still given without regard to the time of the day. Variation in dosing time is generally related with the effectiveness and toxicity of many drugs. On the other hand, several drugs affect the circadian clock. The knowledge of interactions between the circadian clock and drugs is valuable in clinical practice. The pharmacodynamics and pharmacokinetics of the medication influence the chronopharmacological phenomena and recent advances in it have made the traditional goal of pharmaceutics rather outdated. Enhanced progress in chronopharmacotherapy can be achieved if an identification of a rhythmic marker for selecting dosing time is done. However, technology involved in development of drug delivery systems (DDS) that match the circadian rhythm, and the unraveling of the relationship between circardian clock and pathology may be the hindrance in its prosperity for now. The Chronopharmaceutical Drug Delivery System (CDDS) has emerged during the last decade as a possible drug delivery system against several diseases, which may lead to the creation of a sub-disciple of pharmaceutics to be explored called ‘chronopharmaceutics’. The review addresses the approaches to this sub-discipline, call attention to potential disease-targets, identifies existing technologies, hurdles and future of chropharmaceuticals. Chronopharmaceuticals coupled with nanotechnology could be the future of DDS, and lead to safer and more efficient disease therapy in the future.
Keywords: Chronopharmaceuticals, models, circadian, chronopharmacokinetics, oscillation, endogenous, microfabrication, ulcers, osteoarthritis, asthma, hepatic, flourescent, polyelectrolyte gels, hyrophilic, hydrophobic, chronobiological, modelling
Current Pharmaceutical Design
Title: Chronopharmaceuticals: Hype or Future of Pharmaceutics
Volume: 17 Issue: 15
Author(s): Anil K. Philip and Betty Philip
Affiliation:
Keywords: Chronopharmaceuticals, models, circadian, chronopharmacokinetics, oscillation, endogenous, microfabrication, ulcers, osteoarthritis, asthma, hepatic, flourescent, polyelectrolyte gels, hyrophilic, hydrophobic, chronobiological, modelling
Abstract: Drugs for several diseases are still given without regard to the time of the day. Variation in dosing time is generally related with the effectiveness and toxicity of many drugs. On the other hand, several drugs affect the circadian clock. The knowledge of interactions between the circadian clock and drugs is valuable in clinical practice. The pharmacodynamics and pharmacokinetics of the medication influence the chronopharmacological phenomena and recent advances in it have made the traditional goal of pharmaceutics rather outdated. Enhanced progress in chronopharmacotherapy can be achieved if an identification of a rhythmic marker for selecting dosing time is done. However, technology involved in development of drug delivery systems (DDS) that match the circadian rhythm, and the unraveling of the relationship between circardian clock and pathology may be the hindrance in its prosperity for now. The Chronopharmaceutical Drug Delivery System (CDDS) has emerged during the last decade as a possible drug delivery system against several diseases, which may lead to the creation of a sub-disciple of pharmaceutics to be explored called ‘chronopharmaceutics’. The review addresses the approaches to this sub-discipline, call attention to potential disease-targets, identifies existing technologies, hurdles and future of chropharmaceuticals. Chronopharmaceuticals coupled with nanotechnology could be the future of DDS, and lead to safer and more efficient disease therapy in the future.
Export Options
About this article
Cite this article as:
K. Philip Anil and Philip Betty, Chronopharmaceuticals: Hype or Future of Pharmaceutics, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197151
DOI https://dx.doi.org/10.2174/138161211796197151 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time- and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc. has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions
Current Pharmaceutical Design A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Current Diabetes Reviews Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all
Current Pharmaceutical Design Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease
Current Medicinal Chemistry Cellular and Biochemical Alterations Caused by Artificial Depletion of Glutathione
Current Enzyme Inhibition Antiangiogenesis Drug Design: Multiple Pathways Targeting Tumor Vasculature
Current Medicinal Chemistry NQDI 1, An Inhibitor of ASK1 Attenuates Acute Ischemic Renal Injury by Modulating Oxidative Stress and Cell Death
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolic Imbalance of Homocysteine and Hydrogen Sulfide in Kidney Disease
Current Medicinal Chemistry Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Current Pharmaceutical Design The Role of Antithrombotic Therapy in Heart Failure
Current Pharmaceutical Design Poor Response to Antiplatelet Drugs. An Important Issue in Drug-Eluting Stents.
Current Clinical Pharmacology Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued) Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Inflammatory Biomarkers Predicting Events in Atherosclerosis
Current Medicinal Chemistry Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design EPC Dysfunction and Immune Networks: Translating Opportunities for Clinical Setting in Personalized Medicine
Current Medicinal Chemistry Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)